Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15950982 | 0.81 | APP (0.61) | MAPTKMT2AMAOAMEN1APP | |
| SCHEMBL1520210 | 0.78 | NTRK1 (0.53) | NTRK1PLK3MAPTKMT2AMAOA | |
| SCHEMBL7575236 | 0.77 | NTRK1 (0.55) | NTRK1PLK3MAPTKMT2AMEN1 | |
| SCHEMBL7574891 | 0.76 | NTRK1 (0.44) | NTRK1PLK3MAPTKMT2AMEN1 | |
| SCHEMBL15951030 | 0.75 | ALDH1A1 (0.47) | NTRK1PLK3MAPTKMT2AMAOA | |
| SCHEMBL30704422 | 0.74 | NTRK1 (0.74) | NTRK1PLK3MAPTKMT2AMAOA | |
| SCHEMBL11768754 | 0.74 | NTRK1 (0.74) | NTRK1PLK3MAPTKMT2AMAOA | |
| SCHEMBL7568567 | 0.73 | EGFR (0.56) | NTRK1PLK3KDRMAPTKMT2A | |
| SCHEMBL12766811 | 0.73 | NTRK1 (0.54) | NTRK1PLK3KDRMAPTKMT2A | |
| SCHEMBL2495022 | 0.73 | TERT (0.54) | NTRK1PLK3KDRMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020182232-A9 | Cosmetic composition comprising at least one ingredient chosen from compounds of formula (I) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof | L'OREAL S.A. (FR) | 2002-12-05 | — | — | US | claimed |
| US-20020012683-A1 | Cosmetic composition comprising at least one ingredient chosen from compounds of formula (1) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof | HENRION JEAN-CHRISTOPHE (FR) | 2002-01-31 | — | — | US | claimed |
| EP-1134217-A2 | Cosmetic composition containing a furan-naphthoquinone derivative, use therof as dyeing agent, and derivatives | L'OREAL (FR) | 2001-09-19 | — | — | EP | claimed |
| US-20020182232-A9 | Cosmetic composition comprising at least one ingredient chosen from compounds of formula (I) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof | L'OREAL S.A. (FR) | 2002-12-05 | — | — | US | disclosed |
| US-20020012683-A1 | Cosmetic composition comprising at least one ingredient chosen from compounds of formula (1) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof | HENRION JEAN-CHRISTOPHE (FR) | 2002-01-31 | — | — | US | disclosed |
| EP-1134217-A2 | Cosmetic composition containing a furan-naphthoquinone derivative, use therof as dyeing agent, and derivatives | L'OREAL (FR) | 2001-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020012683-A1 | Cosmetic composition comprising at least one ingredient chosen from compounds of formula (1) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof | CYP1B1, NDUFA2, TYR | NTRK1 4814/4885PLK3 1152/4885KDR 4125/4885 |
| US-20020182232-A9 | Cosmetic composition comprising at least one ingredient chosen from compounds of formula (I) and salts thereof, use thereof as colouring agent, and novel compounds of formulae (IIa), (IIIa), (IVa), (Va), and (VIa), and salts thereof | TYR, SDHA, NDUFA2 | NTRK1 4797/4885PLK3 1017/4885KDR 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.